Antibody-based therapeutics targeting ILDR2, designated by Compugen as CGEN-15001T, for immuno-oncology were licensed to Bayer, while Compugen retains the full rights to the fusion protein ...

Although a few validated immunohistochemistry methodologies have been published for ER, 10, 11, 12, 13, 14 none exist for PR. The few published studies that have ...

Do not miss out and become a member today for free to access this upcoming report at: Compugen, First to Publish Data on ILDR2 as a New Immune Checkpoint with a Therapeutic Role in Auto-Immune ...

nasdaq 100 euro stoxx 50 ftse-100 ...

BAY 1905254 is a novel immune checkpoint inhibitor for cancer immunotherapy targeting ILDR2. BAY 1905254 is a human/mouse cross-reactive antibody designed to block the immunosuppressive activity ...

BAY 1905254, a first-in-class immuno-oncology therapeutic antibody targeting ILDR2 immune checkpoint discovered by Compugen, is currently being evaluated by Bayer in a Phase 1 study in advanced ...

ILDR2 is a new immune checkpoint protein identified by Compugen using its predictive target discovery platform. "ILDR2 was one of the first immune checkpoint targets discovered through our ...

One is CGEN-15001T/ILDR2, which is being developed by Bayer under a 2013 agreement. On February 21, Compugen said Bayer was advancing CGEN-15001T through late preclinical development, with plans ...

The continued development of cancer drug BAY 1905254 is a major boost for Compugen's ability to successfully identify new mechanisms for treatments using its big data systems. ILDR2 is a new ...